Trujillo and colleagues performed a molecular analysis of baseline and treatment-resistant tumor samples from two malignant melanoma patients who initially showed a durable partial response to either a melanoma-peptide/interleukin-12 vaccine or combined anti-CTLA-4 + anti-PD-1 therapy and subsequently developed new treatment-resistant metastases. Here, CTLA4 is linked to neoplasm.